# The 2024 Outsourcing Facilities Association Lawsuit

Canonical source: https://retacompare.com/research/outsourcing-facilities-association-suit-72

FDA · 2026-01-19


    In October 2024 the Outsourcing Facilities Association (OFA) filed suit in the US District Court for the Northern District of Texas challenging FDA's resolution of the tirzepatide shortage. The complaint argued that FDA's shortage determination was arbitrary and capricious under the Administrative Procedure Act, and sought injunctive relief to prevent enforcement. The court denied preliminary injunction and eventually granted summary judgment in FDA's favor, with the decision being appealed. The litigation clarified that courts will give FDA substantial deference on factual shortage determinations, a precedent that has shaped subsequent compounded peptide disputes.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources